Drugs / Capravirine
Capravirine
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00006519 | Nov 2000 → Oct 2004 | HIV infectious disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005673 | May 2000 → May 2002 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00002214 | — | HIV infectious disease | Lexigen Pharmaceuticals | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00052117 | Jan 2003 → May 2005 | HIV infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00051844 | Aug 2002 → Nov 2004 | HIV infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00006211 | Feb 2000 → Apr 2001 | HIV infectious disease | Agouron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00004985 | Jan 2000 → ? | HIV infectious disease | Agouron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00004998 | Nov 1999 → ? | HIV infectious disease | Agouron Pharmaceuticals | Suspended | No outcome recorded |
| Phase 2 | NCT00004999 | Aug 1999 → ? | HIV infectious disease | Agouron Pharmaceuticals | Suspended | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Capravirine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002214 ↗ |
| Known as | AG1549 | “A Phase II, Single-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in...” NCT00004985 ↗3“A Double-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With VIRACEPT and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected...” NCT00006211 ↗ “This is a pediatric phase I dose escalation study to determine a biologically active dose and to obtain information concerning the safety, tolerability, and pharmacokinetics of...” NCT00006519 ↗ “Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen” NCT00051844 ↗ |
| Known as | Capravirina | ChEMBL registry synonym — accepted as the source's own label CHEMBL435128 ↗ |
| Known as | S-1153 | ChEMBL registry synonym — accepted as the source's own label CHEMBL435128 ↗ |
| Action | Inhibit | “non-nucleoside reverse transcriptase inhibitor” NCT00005673 ↗ |
| Modality | Small molecule | — CHEMBL435128 ↗ |